Showing results (1041-1050 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|September 20, 2021
Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance studyXiaolin Li, Gang Chen, Yang Hu, et al.
Anti-Cancer Drugs|February 2, 2023
Growth differentiation factor 15 is required for triple-negative breast cancer cell growth and chemoresistanceYanling He, Xinyuan Zhang, Yunli Zhang, et al.
Anti-Cancer Drugs|February 2, 2023
Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 casesChang-Lu Wang, Yi-Zhuo Zhao, Qin Zhang, et al.
Anti-Cancer Drugs|February 2, 2023
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature reviewXiaoqiong Duan, Baoru Liu, Min Yang
Anti-Cancer Drugs|February 2, 2023
Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case reportXiaoyan Huang, Xiaojian He, Dongliang Li, et al.
Anti-Cancer Drugs|February 2, 2023
Efficacy and safety evaluation of albumin-bound paclitaxel chemotherapy in East Asian patients with gynecological tumors based on the degree of paclitaxel binding to patient plasmaJiahui Liu, Shuo Zhang, Fang Yang, et al.
Anti-Cancer Drugs|February 2, 2023
Cancer-associated fibroblasts-derived exosomes from chemoresistant patients regulate cisplatin resistance and angiogenesis by delivering VEGFA in colorectal cancerYuanyuan Shi, Hua Zhu, Hang Jiang, et al.
Anti-Cancer Drugs|February 2, 2023
Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case studyXu Tan, Qin Wen, Guo Chen, et al.
Anti-Cancer Drugs|February 2, 2023
Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case reportJing Jin, Qidong Yang, Yangyang Yu, et al.
Anti-Cancer Drugs|February 2, 2023
M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2 -activated ZBTB4 expressionBingfeng Guan, Xiaofeng Dai, Yan Zhu, et al.
Pageof 464